Zivo Bioscience, Inc.
ZIVO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001101026
No open-market purchases or sales by Zivo Bioscience, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17.6K in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Zivo Bioscience, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- 0 vs. Q2 2023
- Shares held
- 1.27M
- −207.5K (−14.1%) vs. Q2 2023
- Total value
- $1.65M
- −$1.92M (−53.7%) vs. Q2 2023
- New holders
- 1
- 3 more added
- Sold out
- 1
- 3 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ZIVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $17.6K |
| Q1 2026 | 2 | $30.1K |
| Q4 2025 | 3 | $43.2K |
| Q3 2025 | 2 | $58.3K |
| Q2 2025 | 2 | $60.4K |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 1 | $10.8K |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 2 | $216 |
| Q3 2023 | 14 | $1.65M |
| Q2 2023 | 14 | $3.57M |
| Q1 2023 | 14 | $1.35M |
| Q4 2022 | 15 | $1.13M |
| Q3 2022 | 14 | $1.41M |
| Q2 2022 | 13 | $2.08M |
| Q1 2022 | 14 | $2.05M |
| Q4 2021 | 14 | $1.66M |
| Q3 2021 | 12 | $828.6K |
| Q2 2021 | 8 | $194.7K |
| Q1 2021 | 3 | $55.2K |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Zivo Bioscience, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 170 | $0 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 9 | $12 | 0.00% | −91−91.0% | Reduced |
| Bourgeon Capital Management LLC | 31 | $41 | 0.00% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 629 | $818 | 0.00% | 00.0% | Unchanged |
| Bartlett & Co. LLC | 1,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| Bartlett & Co. Wealth Management LLC | 1,000 | $1.30K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 5,351 | $6.96K | 0.00% | +5,351 | New |
| Verdence Capital Advisors LLC | 10,000 | $13.0K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 11,328 | $14.7K | 0.00% | +10+0.1% | Added |
| Column Capital Advisors, LLC | 12,000 | $15.6K | 0.00% | 00.0% | Unchanged |
| Schechter Investment Advisors, LLC | 21,900 | $28.5K | 0.00% | −350−1.6% | Reduced |
| Vanguard Group Inc | 130,866 | $170.1K | 0.00% | +14,536+12.5% | Added |
| Geode Capital Management, LLC | 272,851 | $360.2K | 0.00% | +630.0% | Added |
| Armistice Capital, LLC | 801,870 | $1.04M | 0.03% | −222,000−21.7% | Reduced |
| BlackRock Inc. | 0 | $0 | 0.00% | −5,021−100.0% | Sold out |